23andme glp-1 Genetic predictors for weight loss efficacy and side effects identified 23andMe Reports Genetic Predictors of

Treatment satisfaction in people with type 2 diabetes mellitus treated with once-weekly dulaglutide: data from the AWARD-1 and AWARD-3 clinical trials

Verywell Health, 2024

The critical rule is maintaining a minimum gap between injections

In a follow-up study from Zhang and colleagues, a role of Nox enzymes during hyperoxia was investigated

Sukumaran and colleagues treated Zucker lean and obese rates with either vehicle or the GLP-1 agonist liraglutide (LIRA) for 8 weeks [66]

Who Should Consider GLP-1 Therapy and Medical Evaluation GLP-1 therapy may be appropriate for individuals with type 2 diabetes, prediabetes, or obesity-related metabolic dysfunction who also have hypertension